Akero Therapeutics, Inc. AKRO NASDAQ

Akero Therapeutics, Inc. (AKRO) reported total assets of $825.89M and total liabilities of $75.77M for fiscal year 2024, resulting in total equity of $750.11M.

The company held $743.08M in cash and short-term investments. Total debt stood at $36.46M, with net debt of $-303.78M. The Debt-to-Equity (D/E) ratio was 0.05 (conservative).

Current ratio is 19.38, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (100/100, Pass) — Debt-to-Equity of 0.05, current ratio of 19.38 — balance sheet is strong
• MOAT (40/100) — Total assets $825.89M and equity $750.11M support the company's competitive scale
• VALUE (20/100) — Debt-to-Equity 0.05 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 36/100 with 1/7 criteria passed.

RVMD

Revolution Medicines, Inc.

$147.01

+7.86%

MDGL

Madrigal Pharmaceuticals, Inc.

$524.99

-0.13%

PTGX

Protagonist Therapeutics, Inc.

$104.72

+7.33%

RETA

Reata Pharmaceuticals, Inc.

$172.36

+0.02%

TERN

Terns Pharmaceuticals, Inc.

$52.68

+0.13%

VKTX

Viking Therapeutics, Inc.

$35.52

+1.46%

STOK

Stoke Therapeutics, Inc.

$35.86

+2.31%

ICPT

Intercept Pharmaceuticals, Inc.

$19.00

+0.21%